SCHEMBL4719072

SCHEMBL4719072

CCCCCCCCCCCCCCCCN(C/C=C(\C)CCC=C(C)C)CCCCCCCCCCCCCCCC

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.53
KMT2A Q03164 3/20 0.47
SQLE Q14534 5/20 0.46
MEN1 O00255 2/20 0.44
CYP3A4 P08684 2/20 0.44
ALOX15 P16050 2/20 0.44
LSS P48449 1/20 0.43
MAPT P10636 2/20 0.43
ALDH1A1 P00352 1/20 0.43
UGT1A1 P22309 1/20 0.43
CNR1 P21554 2/20 0.43
CNR2 P34972 2/20 0.43
TRPV1 Q8NER1 2/20 0.43
TRPA1 O75762 1/20 0.43
INHA P05111 1/20 0.43
SLC6A2 P23975 1/20 0.43
HTR2A P28223 1/20 0.43
SLC6A4 P31645 1/20 0.43
OPRM1 P35372 1/20 0.43
PPARG P37231 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4719073 1.00 KDM4E (0.53) KDM4EKMT2ASQLEMEN1CYP3A4
SCHEMBL10598436 0.93 KDM4E (0.56) KDM4EKMT2ASQLEMEN1CYP3A4
SCHEMBL10760238 0.93 KDM4E (0.56) KDM4EKMT2ASQLEMEN1CYP3A4
SCHEMBL10598442 0.93 KDM4E (0.56) KDM4EKMT2ASQLEMEN1CYP3A4
SCHEMBL28651727 0.93 KDM4E (0.47) KDM4EKMT2ASQLEMEN1CYP3A4
SCHEMBL4762055 0.92 KDM4E (0.49) KDM4EKMT2ASQLEMEN1CYP3A4
SCHEMBL14273788 0.92 KDM4E (0.49) KDM4EKMT2ASQLEMEN1CYP3A4
SCHEMBL22340920 0.90 KDM4E (0.47) KDM4EKMT2ASQLEMEN1CYP3A4
SCHEMBL22340879 0.90 KDM4E (0.47) KDM4EKMT2ASQLEMEN1CYP3A4
SCHEMBL20871423 0.90 KDM4E (0.47) KDM4EKMT2ASQLEMEN1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2004159-A1 AUTOIMMUNE CONDITIONS AND NADPH OXIDASE DEFECTS Biovitrum AB (publ) (SE) 2008-12-24 EP disclosed
US-20080051451-A1 Autoimmune conditions and NADPH oxidase defects BIOVITRUM AB (SE) 2008-02-28 US disclosed
US-20080051451-A1 Autoimmune conditions and NADPH oxidase defects BIOVITRUM AB (SE) 2008-02-28 US disclosed
WO-2007104790-A1 AUTOIMMUNE CONDITIONS AND NADPH OXIDASE DEFECTS BIOVITRUM AB (PUBL) (SE) 2007-09-20 WO disclosed
WO-2007104790-A1 AUTOIMMUNE CONDITIONS AND NADPH OXIDASE DEFECTS BIOVITRUM AB (PUBL) (SE) 2007-09-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080051451-A1 Autoimmune conditions and NADPH oxidase defects CYBB, NOX1, NOX5 KDM4E 2756/4885KMT2A 3330/4885SQLE 45/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.